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Abstract 
 
Telomerase activity imparts eukaryotic cells with unlimited proliferation capacity, one of the 
cancer hallmarks. Over 90% of human urothelial carcinoma of the bladder (UCB) are positive 
for telomerase activity. Telomerase activation can occur through several mechanisms. 
Mutations in the core promoter region of the human telomerase reverse transcriptase gene 
(TERT) cause telomerase reactivation in 60-80% of UCB, whereas the prevalence of these 
mutations is lower in urothelial cancers of other origins. TERT promoter mutations are the 
most frequent genetic alteration across all stages of UCB, indicating a strong selection 
pressure during neoplastic transformation.[Au:We avoid formulations referring to the article 
authors (we) in the abstract. I have edited the following text accordingly, OK?] TERT 
[Au:promoter?] promoter mutations could arise during regeneration of normal 
urothelium[Au:I tried to simplify here; is this what you meant?] and due to consequential 
telomerase reactivation, might be the basis of UCB initiation, which represents a new model 
for the origination of urothelial carcinogenesis. In the future, TERT promoter mutations and 
telomerase activity might have diagnostic and therapeutic applications in UCB. 
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[Au:For your information, [H1] and [H3] denote the level of heading and will be removed during 
the production process. Where indicated, I have edited the headings to conform to the 
character limits of a Perspective article ([H1] 32 characters incl. spaces; [H3] 70 characters incl. 
spaces). Please adjust my edits of headings if you have better suggestions.] 
[H1]Introduction 
Telomerase is a ribonucleoprotein (RNA-containing protein) complex composed of the 
telomerase reverse transcriptase protein (TERT) and a telomerase RNA component (TERC), 
which assemble, in a cell cycle-dependent manner, with several accessory factors to form 
the active holoenzyme 1. Telomerase is a telomere-specific enzyme that extends telomeres 
and its activity is required to overcome the end replication problem, counteracting the 
progressive loss of telomeric DNA at the tips of linear chromosomes during DNA replication. 
In the absence of telomerase activity, telomere shortening would eventually result in the loss 
of genetic material and genetic catastrophe owing to breakage-fusion-bridge (BFB) cycles. 
This cycle involves breakage of unstable chromosome structures (e.g. resulting from end-to-
end-fusion of telomere-dysfunctional chromosomes) which may be broken during mitosis and 
initiate repeated rounds of fusion and breakage, leading to genome instability 2. [Au:Please 
reference. Edit for flow here OK? Please explain in the text what BFBs are. Thanks.] 
Telomerase activity is maintained somatically in many animals, including the mouse, 3-7 but is 
down-regulated during human development and cellular differentiation through transcriptional 
repression of the catalytic subunit TERT gene 8-10.[Au:Please clarify, is DNA expression 
repressed or the enzyme itself inhibited?] In human adult non-germ tissues, TERT expression 
and telomerase activity is restricted to the stem or progenitor cell compartment of some 
tissues and can be activated in some cell types, such as lymphocytes, following proliferative 
stimulation 6,7,11-19.[Au:With emerges did you mean can be activated as edited?] In the 
absence of sufficient telomerase activity, telomeres shorten in proliferating cells during aging 
20,21. Short, dysfunctional telomeres lose capping function and activate DNA-damage 
responses. When DNA damage checkpoints are intact, telomere shortening limits the 
proliferative capacity of human cells and serves as a tumour suppressor mechanism by 
activating cell cycle arrest and senescence (Fig. 1).[Au:Please can you add a brief mention of 
what activates the DNA damage response. Is it the BFBs?] once the replication limit of ~50 cell 
divisions (known as the Hayflick limit) is reached 20-23.[Au:As far as I am aware, strictly 
speaking, the term Hayflick limit is used to describe the number of times a cell can divide 
before excessive telomere shortening and senescence occur. How about reformulating to A 
human somatic cell without telomerase activity usually reaches replicative senescence after ׽50 cell divisions (the Hayflick limit).?] These observations are supported by in vivo data 
that show that telomere dysfunction, in combination with a defective p53 pathway, provokes 
BFB cycles and enhances genomic instability, eventually promoting tumorigenesis 24-27.  
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Telomerase activity is found in ~90% of human carcinomas (about 99% in UCB, see below), 
supporting the idea that activation of telomerase is an essential requirement for the 
immortalization (unlimited proliferation capacity) of human cells 28,29.[Au:Although you 
mention it later on in the text, I think it is important to already mention here how frequent 
telomerase activity is in UCB, especially because you write how frequent ALT in UCB is, so that 
the reader has a clear comparison, OK?] These observations led to the hypothesis that down-
regulation of telomerase activity is a mechanism that protects from tumorigenesis. In line with 
this hypothesis, telomerase[Au:add activity for specificity?] activity is required for malignant 
conversion of primary human cells 30.  Tumours without telomerase maintain their telomere 
functionality via the alternative lengthening of telomeres mechanism (ALT) 31.[Au:Please 
could you add a short explanation of what ALT involves?] Stabilization of telomere length and 
functionality by ALT relies on homologous recombination of telomeric DNA between sister 
chromatids 32. Recurrent mutations in the death-associated protein (DAXX) and the alpha-
thalassemia X-linked protein (ATRX) have been correlated with ALT occurrence and 
potentially contribute to ALT maintenance 33,34. Of note, there is evidence that telomerase 
activity supresses ALT, although the suppressive mechanism  is yet to be identified 34-47. In a 
comprehensive analysis of 6,110 human tumour specimens from various cancer types, ALT 
was observed in only ~4% of samples 48. Importantly, the prevalence of ALT varied between 
cancers. Most astrocytomas and sarcomas rely on ALT 48-50, whereas telomerase activity is 
the primary mechanism for telomere maintenance in most other carcinomas 
48,51.[Au:Swapped sentence parts for flow, OK? I also deleted the specific examples, as they did 
not seem relevant.] In urothelial carcinoma of the bladder (UCB), the prevalence of the ALT 
mechanism is low (~1%), indicating the importance of telomerase in this type of cancer 48. 
 
Accumulating evidence shows that telomerase or its components have functions, 
independent of telomere lengthening, which affect many biological processes, including cell 
survival and apoptosis, DNA damage repair, mitochondrial function, cell adhesion and 
migration, and stem cell activity 34,52-61. These alternative functions can be independent of the 
enzymatic activity of telomerase 62 and can involve activation of the WNTß-catenin 
signalling pathway by TERT 52,59.[Au:We avoid the use of the ambiguous may; is can here 
OK or would might be better?] However, the physiological relevance of the latter 
mechanism has been questioned 57,63.[Au:Please excuse my ignorance but I am not sure how 
the previous thought (activation of the WNTß-catenin signalling pathway by TERT) and the 
processes in the following sentence (NFțB-dependent gene regulation 48 or ribosomal 
DNA[Au:OK?] transcription by RNA polymerase 1) are connected. Please could you elaborate 
in the text, so that also readers who are not familiar with these pathways can follow your 
discussion? Also, are you indicating that these pathways are relevant in tumorigenesis? If so, 
please mention specifically in the text, so that the reader is aware why these findings are 
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mentioned in this Review.] Telomerase activity is required, but the presence of[Au:OK?] 
TERT alone is insufficient to modulate NFțB-dependent gene regulation 64 or ribosomal 
DNA[Au:OK?] transcription by RNA polymerase 1 65.  
Data are emerging that show that telomeres can sense cellular stress conditions and 
induce cellular senescence to protect from tumorigenesis 66-68.[Au:Please reference.] The 
cellular stress conditions can originate from chromosomal imbalances such as aneuploidy, 
oxidative damage, or hyperproliferation signals resulting from oncogene activation.[Au:What 
specifically do you mean by chromosomal imbalances. Please specify in the text. Please 
reference.] 46,66,69,70. Telomeres are able to form G-quadruplex (G4) structures, four-stranded 
nucleic acid structures that have been observed in guanine-rich DNA-regions 50,71-73.[Au:OK? 
Please reference. Please explain what G-quadruplex structures are.] G4 structures 
preferentially form during replication and transcription and could be detected at telomeres 74. 
Current understanding is that the G-quadruplex structures impose a challenge to the 
replication machinery if not resolved properly 10,75,76. Human telomeres contain 2,0003,000 
TTAGGG repetitions, which distinguishes telomeres from the rest of the genome and 
provides the basis for sensing genotoxic and oncogenic cell damage 77-82.[Au:I think that we 
need some discussion of how the TTAGGG repetitions can serve as DNA damage sensors. I 
understand that this can be a large topic but the basic concept of how this mechanism works 
needs to be explained to reader. Please add. Thank you.] There is evidence that the activity of 
specific helicases is required for the progression of the replication machinery to prevent 
replication fork stalling. Importantly, it was demonstrated that Pif1 helicase requires 
telomerase to resolve G4-structures at telomeres in Saccharomyces cervisiae 83. Based on 
these observations, it was suggested that in the absence of telomerase, fork progression is 
impaired at telomeres due to replication fork stalling which finally can lead to DNA-double 
strand breaks 77. Importantly, the oncogene-induced senescence (OIS) or aneuploidy-
induced senescence (AIS) response is independent of telomere length and can be reduced 
by telomerase activity (Fig. 2) 46,68,84,85. These data open a new perspective on the interplay 
of telomeres and telomerase in suppressing and promoting tumorigenesis 43,69.[Au:By using 
new perspective, it sounds a bit as if a previous view of the interplay of telomeres and 
telomerase in suppressing and promoting tumorigenesis exists. I am not really sure whether 
this is what you want to indicate and also what that previous theory was. Please clarify, and if 
you want to highlight that this is a change from previous paradigms then please summarize the 
previous paradigm of the interaction in one sentence, so that the reader can quickly grasp the 
difference. Thank you.] This new idea indicates that in addition to the telomere shortening-
induced tumor-protective function as described in Fig. 1, telomeres can act as a barrier to 
tumor progression under conditions such as oncogene-induced hyperproliferation, genotoxic 
oxidative damage or the presence of aneuploidy-inducing mutations (Fig. 2). Consequently, 
suppression of OIS or AIS by telomerase might enable telomerase-positive cells to acquire 
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tumour-initiating mutations that would normally trigger telomere-mediated senescence in 
telomerase-negative cells 43. How the activity of telomerase can suppress the telomere-
length-independent protective function of telomeres is still unclear. 
 
In this Perspectives, we examine recent data showing a high prevalence of TERT promoter 
mutations in UCB, which occur early during tumorigenesis indicating that the biology of the 
urothelium provides a selection pressure for this change. [Au:Please state specifically which 
data.] We consider the implications of telomerase activity for UCB [Au:Might it be better to 
specify UCB?] cell survival in the context of telomere length-dependent and telomere 
length-independent roles of telomerase. We specifically also discuss the role of OIS and AIS 
abrogation in tumorigenesis.[Au:OK?] We present a new model for urothelial carcinogenesis 
that incorporates the role of telomerase activation and the potential of targeting telomerase 
as a therapeutic approach for UCB.  
 
[H1]Telomerase in normal urothelium 
Under physiological conditions, normal human urothelium is a long-lived, mitotically 
quiescent tissue with a low cell turnover rate but can develop a strong regenerative response 
and switch to a proliferative phenotype in response to damage 86-88. In non-proliferating 
urothelium, telomerase is undetectable, but various reports have shown normal human 
urothelial (NHU) cells maintained in vitro as rapidly proliferating, finite (i.e. non-immortalized) 
cell lines to express transient, low-level telomerase protein expression and enzyme activity 
11,13.[Au:What are the in vitro conditions used to achieve proliferation? Please add, so that the 
reader can distinguish from the immortalized NHU cells mentioned below.] Whether 
telomerase becomes activated in human bladder urothelium in situ in response to 
physiological stress or regenerative conditions is not known. The regulatory mechanisms 
underlying the repression of telomerase activity in quiescent human urothelium and its 
activation during proliferation of NHU cells remain to be revealed. Transient, low-level 
telomerase expression and activity might be involved in physiological regeneration of the 
tissue, but stable overexpression of TERT or clonal expansion of cells with a mutated TERT 
promoter is required for the immortalization of NHU cells 13,41,89. Of note, immortalization of 
NHU cells is dependent on the fully functional telomerase holoenzyme, as a C-terminal 
tagged TERT-HA (TERT protein, fused to a short marker peptide sequence incorporating 
amino acids 98 to 106 of the human influenza hemagglutinin (HA)_protein) restored 
enzymatic activity but was incapable of inducing immortalization 90.[Au:Please explain what 
TERT-HA is specifically and how this modification changes the enzyme. Does the TERT-HA 
actually elongate telomeres? How was enzymatic activity measured if not by telomere 
elongation?] Telomerase-immortalized NHU cells remain genetically stable under standard 
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growth conditions in vitro 13,91. However, when cultured under stress-imposing low-density 
conditions, genomic alterations that are similar to those seen in primary urothelial 
tumours[Au:specifically urothelial tumours?] can occur, such as loss of chromosomal region 
2q 91. In line with the extratelomeric functions of telomerase, forced expression of TERT in 
NHU cells results in loss of differentiation capacity13,90 and gene expression changes 
including overexpression of the polycomb repressor complex (PRC1 and PRC4) 
components, BMI1 and SIRT1, and down-regulation of multiple PRC targets and genes 
associated with differentiation 90).[Au:Please give some examples of what specifically 
happens.] 
 
[H1]Telomerase and TERT promoter mutations 
Telomerase activity, determined by the PCR-based telomerase repeated amplification 
protocol (TRAP) assay, has been found in 80100% of UCB, but only in 25% of specimens 
from adjacent normal urothelium 92-94. Similarly, telomerase activity was detectable in 62
100% of urinary samples from patients with UCB 92-94.  To date, only one study has 
implicated specific transcription factors in the regulation of telomerase activity in UCB cells 95. 
Ectopic expression of the c-MYC oncoprotein activated TERT transcription and telomerase 
activity, whereas its counterpart MAD1 (mitosis arrest deficiency 1) had a repressive effect. 
Whether c-MYC and MAD1 affect telomerase activity in urothelial cells under physiological 
conditions is unknown.  
 
Mutations in the promoter of the human TERT gene have been found in several cancer 
types, including UCB, and are the most common non-coding somatic mutations in cancer 
58,96-101. Of all UCB samples, 5583% had TERT promoter mutations at one of the two 
positions responsible for maintaining telomerase activity in cancer cells 44,102-104.[Au:Add 
ref#83 also here?] Nine benign proliferative urothelial lesions (cystitis, nephrogenic adenoma, 
and inverted papilloma) only had the wild-type TERT promoter sequence 44.[Au:OK? How 
specifically were these samples matched to the cancer samples?] These observations indicate 
that urothelial cells with TERT promoter mutations arise de novo in a wild-type setting and 
that the mutation provides a selective advantage to the cell. The evidence further indicates  
that TERT promoter mutations have a tissue-specific role in urothelial tumorigenesis, being 
reported in different histological variants of primary bladder cancer, including small cell 
carcinoma.  In the case of bladder adenocarcinoma, TERT promoter mutations were 
restricted to non-enteric type rather than enteric-type adenocarcinomas (the latter being 
typically of urachal or metastatic colorectal derivation) 39,44.[Au:Please specify: which type are 
urachal or metastatic colorectal  nonenteric or enteric?] Nevertheless, other tissue-regulatory 
factors might contribute to telomerase activity, as >90% of upper tract urothelial cancers 
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(UTUCs) encompassing renal pelvic carcinomas and ureteric cancers have telomerase 
activity 105,106, but only 43% and 19% of these tumours contain the two common TERT 
promoter mutations, respectively 107. These findings suggest that alternative regulatory 
mechanisms contribute to establishing telomerase activity[Au:OK?] in UTUC compared with 
UCB, possibly owing to their different embryological derivations. Similarly, a particularly high 
prevalence of TERT promoter mutations (100%) has been reported for micropapillary 
urothelial cancer 108.   
The two key positions for mutations in the TERT promoter are C228T and C250T (located at 
positions -124 and -146, respectively, relative to the ATG start codon) 100,109-111. Mutations in 
the TERT coding region are rare (frequency < 0.5%) 112, but TERT promoter mutations occur 
in 60-80% of UCB samples and the C228T and C250T mutations together account for 99% 
of these mutations. Convincing experimental evidence exists that both these mutations 
create novel binding sites for the heterotetrameric GA-binding protein (GABP) transcription 
factor,[Au:Are you referring to a specific subunit or the whole factor GA-binding protein?] 
resulting in increased transcription of TERT and activation of telomerase 97,103,113.  
 
[H1]TERT mutations as prognostic markers 
 
Several studies have examined potential associations of TERT promoter mutations with UCB 
stage and grade. The studies report TERT promoter mutations in 59 to 79% (mean 70%) 
UCB irrespective of tumour stage or grade 44,100,102,114,115.[Au:What specifically were these 
rates; could you provide a range of values?] One team of researchers assessed disease-
specific survival in correlation with TERT promoter mutations and TERT mRNA levels in two 
independent cohorts of chemotherapy-naïve patients (n = 35; n = 87), finding that the 
abundance of TERT mRNA, rather than promoter mutation itself, correlated strongly with 
reduced disease-specific survival 104.[Au:Please can you mention the number of patients for 
context.] They further showed that TERT promoter mutations correlated with TERT mRNA 
abundance, telomerase activity, and telomere length, compared with telomerase-positive 
cells without TERT promoter mutations. These observations might also explain the results 
obtained by another group, who analysed urine samples of 230 patients with non muscle 
invasive bladder cancer (NMIBC) and 25 samples of patients with muscle invasive bladder 
(MIBC) cancer. They found TERT promoter mutations to be most common mutation detected 
(52% across of all samples) and showed significant associations between TERT promoter 
mutation and progression of NMIBC to MIBC (9 of 110 patients who progressed had TERT 
promoter mutation versus 1 of 109 patients without). When NMIBC were stratified by risk, the 
presence of TERT promoter mutation was highly associated (p<0.0001) 40. [Au:Please can 
you mention the number of patients for context?] Also of note, TERT promoter mutations 
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were found to be associated with distant metastases in UTUC 107, suggesting a selective 
advantage. In another study, sequencing of 76 urothelial carcinomas demonstrated TERT 
promoter mutations in both low-grade and high-grade UCB, as well as in flat and papillary 
lesions 116.[Au:How does this finding relate to the results by Critelli? Did Kinde not see a 
difference in abundance depending on UCB grade? Why might this discrepancy exist? Please 
discuss in the text.] The same mutations were also detectable in urine and were strongly 
associated with UCB recurrence, providing a potential prognostic[Au:OK?] urinary biomarker. 
The potential to use TERT promoter mutations as a urinary biomarker to detect UCB was 
explored  in a prospective study using samples from 475 patients, which showed that TERT 
promoter mutations had the highest sensitivity (81.8%) but also the lowest specificity (83.5%) 
(among the markers tested: TERT, FGFR3, SALL3, ONECUT2, CCNA1, BCL2, EOMES, and 
VIM) to detect UCB 117.[Au:Please mention which the other tested markers were for context.]  
 
[H1]TERT promoter mutations and cancer initiation[Au:Change to conform to character 
limit OK?] 
 
Mutations that occur in adult stem cells are believed to have the largest effect on the 
mutational load of tissues, owing to their capacity to give rise to all descendant cells in a 
tissue 118,119. Stem cell tracing experiments support this idea by showing that mutations that 
occur in stem cells are efficient cancer drivers, whereas the same mutations in differentiated 
cells fail to initiate cancer 120. This view is supported by reports showing the accumulation of 
mutations in adult stem cells during life 37. However, stem cells are rare and considered to 
divide infrequently, giving rise to a rapidly-expanding supra-basal compartment of highly 
proliferating transit-amplifying cells.  In the past 5 years, an alternative cancer cell origin 
theory has emerged in favour of the transit-amplifying cell population.  121-123.[Au:We avoid the 
use of recently as it can be interpreted differently by different readers; In the past 5 years 
instead OK? Also, please explain in the text what transit-amplifying cells are.] This concept 
takes into account that mutation rates are increased in replicating cells 121 and that most 
heritable mutations occur in the transit-amplifying cells that constitute the majority of the stem 
or progenitor cell pool, rather than in the small number of rarely-dividing adult stem cells (Fig. 
3).  
 
The presence and nature of stem cells in human bladder urothelium is still under debate, but 
studies in animal models indicate that subpopulations of bladder urothelial cells (either P63-
positive, SHH-positive, KRT5-positive, or KRT14-positive subpopulations)[Au:For specificity: 
Do you indicate three subpopulations (P63+, SHH+, and KRT5+/KRT14+) or four 
subpopulations (P63+, SHH+, KRT5+, and KRT14+) here?] confer self-renewal ability and are 
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considered to constitute the stem or progenitor cell population of the bladder epithelium 124-
127. In one study in mice, KRT14-positive cells, which are a subpopulation of KRT5-positive 
cells, gave rise to all cell types of the urothelium during injury-induced regeneration and were 
regarded as the cells of origin of urothelial cancer 128. By contrast, studies with mouse and 
pig urothelial cells suggest that both the basal and intermediate cells can contribute to the 
regenerative potential of the bladder urothelium, indicating that a stringent requirement for a 
stem cell population does not apply to bladder urothelium 88,129. These studies might be 
helpful in understanding the contribution of different cell types to bladder regeneration and 
cancer in different species but, unlike in human somatic tissues, telomerase is constitutively 
expressed in all mouse tissues 5,6.[Au:Please reference again.] Thus, irrespective of the stem 
cell debate, the common occurrence of TERT promoter mutations that result in constitutive 
telomerase activity demonstrates the critical importance of this tumour suppressor in human 
UCB.[Au:Please can you reformulate here and specify what exactly the tumour suppressive 
block is in this context?]  
 
In a series of experiments performed on cell fractions enriched from isolated UCB and 
normal urothelium, one team of researchers located TERT promoter mutations (primarily the 
C228T mutation) in basal cells (defined as CD44+ CK5+ CK20-) from UCB but not from 
normal urothelium (normal bladder basal cells; NBBC) 130.[Au:Deletion of lin- OK, as 
seemed not required to define cell population?] Furthermore, these TERT promoter mutations 
were enriched in basal compared with non-basal bladder cancer cells. Importantly, restoring 
the C228T mutation to the wild-type sequence abolished the tumour-forming ability of 
bladder cancer cells in mouse xenograft experiments. Conversely, basal urothelial cells 
isolated from [Au:human?] non-cancerous adjacent human bladder tissue expressed wild-
type TERT and only developed xenograft tumours in nude mice when the C228T mutation 
was introduced at the genomic level, suggesting that TERT promoter mutation is a crucial 
event in the malignant transformation of human urothelium 130. Pending formal 
demonstration, these data suggest that tumour-adjacent normal bladder urothelial cells have 
accumulated cancer-initiating genetic mutations that are not sufficient for malignant 
transformation by themselves but require activation of telomerase as the tumour-promoting 
step.[Au:Please excuse if I missed it but does any evidence exist that the tumour-adjacent 
normal urothelial cells have other mutations already? The reader might wonder whether the 
TERT mutation could not also be sufficient for malignant transformation by itself. Please 
explain the dependency on other pre-existing mutations in the text. Thank you.] Of note, it was 
demonstrated that telomerase is not an oncogene per se (Harley, 2002). One further 
observation from the above mentioned study was that human [Au:human?]NBBCs had no 
telomerase activity 130. This feature differentiates NBBCs from intestinal stem cells and 
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haematopoietic stem cells, which have a constitutive telomerase activity.[Au:Please add the 
values for comparison and reference.] Consistent with the reports showing transient activation 
of telomerase in normal urothelial cells in culture 11,13,[Au:Please reference again.] it seems 
plausible that NBBCs might be able to up-regulate telomerase[Au:add expression?] 
expression transiently in response to regenerative signals.  
 
The implications of these data in the context of cancer-initiating cells require further 
clarification.[Au:We avoid open questions in our articles. Reformulated sentence OK?] 
[Au:activity or expression; please add.] The presence or absence of telomerase activity in 
resting NBBCs has to be demonstrated unequivocally, but current data indicate that these 
cells are telomerase-negative 130 . In the absence of telomerase, harmful cancer-initiating 
mutations, such as oncogene activation (leading to OIS) or aneuploidy-inducing mutations 
(leading to AIS), would interfere with cell fitness and would induce premature senescence as 
a tumour suppressor mechanism (Fig. 2).[Au:Are you referring to OIS and AIS here, which are 
mediated through the sensing ability of the telomeres specifically? I think the reader needs to 
be reminded of this connection here. In addition, please do ensure that you describe in more 
detail how this sensing works at the beginning of the article where I have asked for it. Thank 
you.] We therefore suggest that, in UCB, the first tumour-initiating mutation is likely to be a 
telomerase re-activating mutation (for example, in the TERT promoter) in cells that have 
been activated for proliferation (Fig. 3).[Au:I think to make this point, you need to ensure that 
you sufficiently discuss earlier in the text the activated for proliferation mutations that 
already exist in cells. Please add above where I have asked for it.] Telomerase activity could 
then facilitate the survival of cells with secondary cancer-promoting mutations[Au:Do you 
mean that these cancer-promoting mutations occur after the telomerase activating mutations? 
Are these then different from the activated for proliferation mutations mentioned in the 
preceding sentence? Please clarify.] and prevent entry into cellular senescence. The fact that 
TERT promoter mutations occur preferentially or exclusively in tissues that have low or 
absent telomerase activity in their non-proliferating cells, such as bladder urothelium 
98,99.[Au:Please reference again.] supports this hypothesis. In fact, high rates of TERT 
promoter mutations have been observed in liver cancer, and the liver is another mitotically 
quiescent highly regenerative tissue in which the identity of stem cells has not been 
clarified.[Au:Edit for clarity OK? Is this also from ref#6, please reference.] Human hepatocytes 
are telomerase-negative in the resting state but can up-regulate telomerase activity following 
stimulatory signals during regeneration 7.   
 
In a study published in 2015, researchers introduced the common TERT promoter mutations 
into human embryonic stem cells (hESCs) and demonstrated that these mutations prevented 
down-regulation of the TERT promoter and telomerase activity during differentiation of these 
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mutant hESCs but not wild-type hESCs 131. These data indicate that TERT promoter 
mutations that occur in stem or progenitor cells prevent differentiation and the shortening of 
telomeres.[Au:You seem to only mention that telomerase activity is maintained but do not 
mention any readouts that relate to differentiation or specifically to telomere shortening. Were 
the researchers testing for these effects? Please provide further evidence to back up your 
statement. ] By contrast, the absence of TERT promoter mutations in cancers arising from 
highly proliferative tissues with a stem cell compartment 38,132. [Au:Please add examples and 
reference.] might be explained by the inherently high telomerase activity of their stem cells 35. 
This hypothesis assumes that, if the stem cells are the origin of TERT promoter mutations, 
the mutation rate of the TERT promoter would be expected to occur at a similar rate in all 
tissues.  
 
[Au:I feel like this final summary of the proposed mechanisms would benefit immensely from 
an accompanying Figure. It seems that several different events occur in different sequence in 
different models. Please could you draft a schematic that summarizes this model?] 
In summary, we hypothesize that TERT promoter mutations occur in telomerase-negative 
cells that are activated for proliferation on demand. It is known that injury and physiological 
stimuli can induce telomerase activity in human tissues 133-136. It was also shown that human 
TERT promoter is activated in response to liver injury in a mouse model carrying a human 
TERT promoter fragment in front of the lacZ reporter gene 7. In the bladder urothelium, it 
seems plausible to assume that TERT promoter mutations occur in proliferating cells that 
have transiently activated telomerase in response to injury, which is in line with the 
alternative model of transit-amplifying cells as the cancer-initiating cells with the highest 
mutation rate (Fig. 3).[Au:Please excuse if I missed it, but did you discuss evidence that 
telomerase is transiently activated in response to injury in bladder cells? If so please briefly 
reiterate here and reference.] Most notably, no TERT promoter mutations could be found in an 
carcinogen-induced bladder cancer model that otherwise shows a mutational signature 
similar to human bladder cancer (e.g. Trp53) and recapitulates the molecular alterations of 
human muscle invasive bladder cancer 137. The lack of TERT promoter mutations in this 
mouse model can be explained by the constitutive TERT gene expression (and constitutive 
telomerase activity) in mouse tissues as described above 3-7. In light of the novel findings that 
telomerase can suppress senescence induction caused by genome instability (AIS) or 
oxidative stress (OIS),[Au:Please reference. Is this OIS and AIS? Please excuse if I missed it, 
but I am not sure that you explain these specific findings in detail. Please expand the 
description of the studies that demonstrate these mechanisms.] we extend this model to 
suggest that TERT promoter mutations are likely to be the first tumour-initiating mutations in 
tissues that lack telomerase activity in their non-proliferating cells. Interestingly, the lack of 
TERT promoter mutations in primary bladder adenocarcinoma suggests that this entity might 
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have a different origin of cancer 138. This idea might also support the conclusion regarding 
the cell type of origin for UTUC,[Au:OK?] in which a low rate of TERT promoter mutations is 
observed despite activation of telomerase in the vast majority of UTUCs 105-107. In urothelial 
tumours (of any origin) that lack TERT promoter mutations, whether telomerase reactivation 
is a late event caused by telomere dysfunction initiated genome instability or whether 
telomerase reactivation occurs early during cellular transformation, potentially promoting 
tumorigenesis by telomere-length-independent mechanisms, remains to be elucidated. Of 
note, telomerase reactivation is not the primary tumour-initiating event in these tumour types 
but might result from loss of negative regulatory factors that suppress TERT promoter activity 
[Au:activity?] in normal cells and/or from an aberrant[Au:as in increased?] increased 
expression of factors that positively regulate TERT gene expression 43. 
 
[H1]Opportunities in diagnosis and therapy 
 
The high frequency of specific TERT gene promoter mutations across all UCB grades and 
stages and its absence from adjacent histologically normal urothelium indicates an important 
function in both neoplastic transformation and maintenance of UCB 44,100,102,114,115.[Au:Please 
reference again.] This finding has led several groups to examine whether detection of TERT 
promoter mutations could be a urinary marker for bladder cancer detection 102.  A non-
invasive liquid biopsy approach is highly attractive139, as it might replace costly long-term 
cystoscopic surveillance for recurrence of low-grade non-invasive UCB and function as a 
screening tool for detecting UCB (particularly early detection of MIBC) in high-risk groups 
117,140. TERT promoter mutation detected in urine might not only be indicative of UCB but also 
of UTUC or renal cell carcinoma, although TERT promoter mutation rates in these tumour 
types are lower than in UCB 107,141.[Au:Comparator added OK?] One retrospective study has 
indicated that urinary TERT promoter mutation detection is not prognostic of UCB clinical 
outcome 102, but it might be a suitable marker for monitoring of disease recurrence 
104.[Au:Please move ref of study showing no prognostication to before the comma.]  However, 
large prospective studies are awaited to determine the value of any clinical test on the basis 
of TERT promoter mutation detection 142.  
The presence of telomerase activity in most human cancers, along with mouse model data 
indicating its requirement for tumour progression, has inspired the development of 
telomerase inhibitors and their testing in preclinical studies 19,143-148. UCB is a good candidate 
for telomerase-based therapies, as most UCBs are telomerase-positive. The first generation 
of inhibitors targeted telomerase activity itself, for example by stabilising the G-quadruplex 45. 
The first of these inhibitors to enter phase II trials, imetelstat, showed promising clinical 
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activity against myeloproliferative neoplasms rather than solid tumours 149-151.[Au:I am not 
sure that this study tested imetelstat also in solid tumours, which you currently seem to 
indicate. Please clarify. Was imetelstat tested in different tumour types in another study?] This 
finding indicates the need to identify novel targets on the basis of the specific molecular 
understanding of telomeric and cancer-associated extra-telomeric functions of telomerase in 
UCB 34.  
Alternative targeting of telomerase activity has been investigated with the nucleoside 
analogue 6-thio-2ƍ-deoxyguanosine. This compound is a telomerase substrate precursor that 
becomes incorporated into telomeric DNA by telomerase during DNA replication, resulting in 
rapid telomere deprotection and apoptosis in telomerase-positive cancer cell lines originating 
from colon, (HCT116), from lung (A549) or liver (HCC15) while telomerase negative primary 
human fibroblasts (BJ) or telomerase-negative but ALT-positive immortal human fibroblast 
(AV13) were resistant to the treatment 152,153.[Au:Which cells (tumour type) specifically? Also, 
please explain a bit more what telomere deprotection is. Thank you.] The protein components 
of the telomere-protective shelterin complex, a complex of six protein components (telomeric 
repeat-binding factor 1 and 2 (TERF1 and TERF2, also known as TRF1 and TRF2), TRF2-
interacting protein 1 (TERF2IP, also known as RAP1), TRF1-interacting nuclear factor 2 
(TINF2, also known as TIN2), protection of telomeres protein 1 (POT1), and tripeptidyl-
peptidase 1 (TPP1)) that specifically associate with telomeres, also offer alternative targets. 
These shelterin components protect telomere length and structure, partly by regulating 
telomerase activity and access to the telomeric DNA 154. In cells with dysfunctional telomeres, 
chromosome ends are no longer protected efficiently by the shelterin components. These 
unprotected telomeres resemble chromosome breaks and activate the DNA-damage 
response 155-157. Furthermore, they are prone to degradation by exonucleases and lose their 
capping function to protect from end-to-end fusions or loss of genetic material. This process 
of telomere-uncapping and de-protection can be induced by progressive telomere shortening 
in the absence of sufficient telomerase activity as well as by mutant or genetically-modified 
shelterin proteins, resulting in activation of p53-dependent senescence and/or apoptotic 
responses 158. PINX1 is of particular relevance in UCB, as it encodes a shelterin-recruited 
telomerase-regulatory protein and displays single-nucleotide polymorphisms that are 
associated with significantly reduced bladder cancer risk 159-161.[Au:Journal style is to use 
significant only in a statistical context. Please add the P value or change to e.g. 
substantially OK?] Hence, specific targeting of shelterin components or telomerase-
associated proteins could be a useful strategy to modulate telomerase activity for UCB 
therapy. 
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In addition, evidence of non-canonical, extra-telomeric functions of telomerase and their 
utility as treatment targets is accumulating. As an example, eribulin, an anticancer drug that 
interferes with microtubule elongation, inhibits the RNA-dependent RNA-polymerase activity 
of telomerase 162. Further understanding of the non-canonical roles of telomerase has 
potential for developing new cancer-specific therapeutics. 
As the prevalence of the ALT mechanism is low or absent in UCB, telomerase targeting can 
be considered a promising first-line strategy. However, secondary activation of the ALT 
mechanism is a potential drawback of any telomerase-inhibiting therapy. Studies in a 
lymphoma-prone mouse model have shown that deletion of telomerase in tumours provoked 
activation of ALT in cancer cells as an adaptive response 163.[Au:Which tumours 
specifically?] Whether ALT activation is of concern in [Au:human?] human UCB is not yet 
clear, but research on the potential telomere-length-independent functions of telomerase 
gives reason to hope that telomerase inhibition might result in a telomere-length-independent 
senescence response that protects from tumorigenesis without activating the ALT 
mechanism.  In the meantime, ALT itself remains a potential target.[Au:Ive changed 
proleptic to potential, as Im not sure all readers would understand. Is this the meaning you 
had in mind?] 
 
[H1]Conclusions 
The high prevalence of telomerase activity in UCB and identification of two hot-spot 
mutations within the TERT promoter region as the most frequent genetic alteration across all 
disease stages indicate a very strong selection pressure for telomerase activation during 
neoplastic transformation. Three conclusions can be drawn from our current understanding 
of telomerase function in the initiation and maintenance of UCB and the prospects for 
developing cancer-specific therapies. First, TERT promoter mutations resulting in telomerase 
overactivity occur in telomerase-negative cells that reside in tissues without a well-defined 
telomerase-positive stem cell compartment.  Notably, a potential transient function of 
telomerase in the regenerative response of urothelium remains an open question. Secondly, 
the observations that TERT promoter mutations are detectable in all stages of UCB, but not 
overtly normal urothelium, indicate that telomerase activation provides a survival advantage 
during the initial stages of urothelial tumorigenesis.  This notion is in line with the non-
canonical functions of telomerase in the abrogation of AIS and/or suppression of OIS.  Thus, 
in the absence of telomerase, harmful cancer-initiating mutations, such as oncogene 
activation or aneuploidy-inducing mutations, would interfere with cell fitness and induce 
premature senescence as a tumour suppressor mechanism through sensing by 
telomeres.[Au:through sensing by telomeres, or also alternative mechanism? Please clarify.] 
By contrast, urothelial cells that acquire telomerase-activating TERT promoter mutations 
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obtain a survival advantage. This insight might lead to new strategies for cancer therapy. 
Finally, on the basis of the alternative cancer cell origin theory which suggests the transit-
amplifying cells as the cell of origin of cancer, as described above 122,123,[Au:Instead of 
mentioning the researcher names, please refer to (explain) this model as you have done in the 
main text above, so that the reader immediately knows what you are referring to.] TERT 
mutations should occur in proliferating rather than in mitotically quiescent urothelial cells. 
These cells with TERT promoter mutations [Au:with TERT mutations?] are probably the 
cancer-initiating cells, which then accumulate additional oncogenic mutations during UCB 
progression. Consequently, detection of TERT promoter mutations in body fluids might be an 
early marker of UCB and potentially for early cancer therapy by targeting telomerase.  
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Figure Legends 
[Au:As you can see in the proofs, I have made some edits to the Figures for clarity and 
consistency with the legends, OK?] 
 
Figure 1 | Classical concept of telomere and telomerase functions in tumour 
suppression and initiation. During the life of differentiated cells, telomere length shortens 
owing to suppression of telomerase expression[Au:OK?]. Short, dysfunctional telomeres 
resemble chromosome breaks, and activate various DNA-damage response mechanism 155-
157. After a maximum number of cell replications (Hayflick limit),[Au:OK?] critically short 
telomeres induce replicative senescence in cells with a functional DNA damage response 
(DDR), serving as a mechanism to protect from tumorigenesis.[Au:Please add why cells with 
overly short telomeres are prone to tumorigenesis  why the DDR would be activated.] In DDR-
deficient cells, overly short telomeres can result in genetic instabilities by repeated breakage-
fusion-bridges (BFB) cycles, that lead to cellular transformation. Transformed cells require 
telomerase activity to stabilize telomere functionality and avoid apoptosis, and for unlimited 
proliferation. Transformed cells in culture and human cancers usually reactivate telomerase 
or employ alternative lengthening of telomeres (ALT) as telomere maintenance mechanisms. 
 
 
Figure 2 | Alternative concept of telomere and Telomerase functions in tumour 
suppression and initiation. a | New data indicate that tumour-initiating mutations (for 
example, an oncogenic mutation) occurring in a telomerase-negative somatic cell (T-) can 
cause telomere replication stress, accumulation of fragile telomeres, and eventual 
senescence independent of telomere length (oncogene-induced senescence (OIS) or 
aneuploidy-induced senescence (AIS). This senescence response prevents tumorigenesis. b 
| When the same mutation occurs in a telomerase-positive somatic cell (T+) with a 
telomerase-reactivating TERT promoter mutation, the mutated cell can continue to 
proliferate.[Au:Please add why telomerase activation prevents senescence or apoptosis in a 
mutated cell.] During continued proliferation,  the cell accumulates additional mutations, 
eventually leading to transformation and cancer. 
 
Figure 3 | The cell of origin of cancer in UCB. In tissues with a defined stem cell 
compartment, stem cells have constitutive telomerase activity, supporting the proliferation of 
stem and transit-amplifying cells. Telomerase activity is subsequently down-regulated in 
differentiated cells arising from the progenitor cells.[Au:OK?] In the mitotically quiescent 
bladder urothelium, including in basal cells, telomerase activity is undetectable. Whether 
telomerase is activated under physiological regenerative conditions in human urothelium in 
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vivo remains to be clarified. In urothelial carcinoma of the bladder (UCB), telomerase is 
activated through TERT promoter mutations (red flash icon), which probably occur in 
proliferating urothelial cells. The activation of telomerase endows continued proliferation of 
cells by preventing telomere shortening and counteracting cellular differentiation. Specifically, 
it was demonstrated that forced expression of TERT in normal urothelial cells results in loss 
of differentiation capacity13,90, potentially  by the down-regulation of components of polycomb 
response complex targets and genes associated with differentiation 90. Cells with TERT 
mutations show sustained proliferation and can accumulate additional mutations (black flash 
icon) that promote malignant transformation.[Au:For this Figure, please clarify the connection 
between the panel with the cells on the left and Cellular differentiation (how is differentiation 
blocked?), and with Mutation load (why does the mutation load decrease again?).]  


